Secoxyloganin

Secoxyloganin is an orally effective iridoid derivative. Secoxyloganin can be isolated from the flower buds of L. japonica. Secoxyloganin induces Apoptosis by inhibiting the expression of Bcl-2. Secoxyloganin potently inhibits the proliferation of breast cancer cells, while exerting weak activity against normal mammary epithelial cells. Secoxyloganin inhibits the decrease in tail vein blood flow associated with allergic reactions^[1][2]. In Vitro:Secoxyloganin (0.37-96 µM; 24 h) potently inhibits the proliferation of breast cancer MDA-MB-231 cells with an IC₅₀ of 6.5 µM, while it shows weak activity against normal fR2 mammary epithelial cells with an IC₅₀ of 38 µM^[1].
Secoxyloganin (6-24 µM) induces concentration-dependent DNA damage in breast cancer MDA-MB-231 cells^[1].
Secoxyloganin (6-24 µM; 24 h) induces concentration-dependent apoptosis in breast cancer MDA-MB-231 cells^[1].
Secoxyloganin (6-24 µM; 24 h) regulates the expression of apoptosis-related proteins in human breast cancer MDA-MB-231 cells, upregulating Bax and decreasing Bcl-2^[1].
Secoxyloganin (6-24 µM) induces G₀/G₁ cell cycle arrest in breast cancer MDA-MB-231 cells^[1]. In Vivo:Secoxyloganin (10 mg/kg; p.o.; administered on days 0, 3, 6, and 9) significantly inhibits the decrease in tail vein blood flow in lysozyme-sensitized mice without affecting platelet aggregation^[2].\n